Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | NPY2R | P49146 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL19211129 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29995613 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL1649321 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29367290 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL4881939 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL41104 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL2124595 | 0.99 | TDP1 (0.98) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL4879331 | 0.98 | TDP1 (0.96) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL28264735 | 0.97 | TDP1 (0.94) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.93 | ADRB2 (0.88) | TDP1PMP22NPY1RNPY2RNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1037 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| US-20240002935-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | GENETICURE INC. | 2024-01-04 | — | — | US | claimed |
| EP-4132653-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | Geneticure Inc. (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115212178-A | Metoprolol tartrate preparation composition and preparation method thereof | 常州市第四制药厂有限公司 | 2022-10-21 | — | — | CN | claimed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | claimed |
| CN-111788196-A | Acetal compounds and their therapeutic use | 配体药物公司 | 2020-10-16 | — | — | CN | claimed |
| EP-1898886-B1 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RES PVT LTD (IN) | 2019-09-04 | — | — | EP | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| US-9629915-B2 | Sustained release dosage form | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-04-25 | — | — | US | claimed |
| EP-1651192-A1 | PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE DRUG | Mulye, Nirmal (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0954291-B1 | SOLUBLE FORM OSMOTIC DOSE DELIVERY SYSTEM | SHIRE LAB INC (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| US-20050129778-A1 | Beads coated with drugs; forming supersaturated solution; controlling temperature | NOSTRUM PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005013939-A1 | PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE DRUG | MULYE NIRMAL (US) | 2005-02-17 | — | — | WO | claimed |
| US-6814979-B2 | TO DISPENSE THERAPEUTIC AGENT HAVING A LIMITED SOLUBILITY IN WATER OR PHYSIOLOGICAL ENVIRONMENTS WITHOUT THE USE OF OSMOPOLYMERS OR SWELLING AGENTS | SHIRE LABORATORIES, INC. | 2004-11-09 | — | — | US | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |